Zacks Investment Research upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a strong sell rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $6.50 price target on the stock.
According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
DPLO has been the subject of a number of other reports. Raymond James set a $28.00 target price on shares of Wheaton Precious Metals and gave the stock a buy rating in a research note on Thursday, March 21st. Mizuho lifted their target price on shares of Diplomat Pharmacy from $6.00 to $8.00 and gave the stock a reduce rating in a research note on Monday, March 18th. Guggenheim began coverage on shares of Patterson Companies in a research note on Wednesday, April 17th. They issued a neutral rating and a $23.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of Yum China from $36.50 to $48.00 and gave the stock an overweight rating in a research note on Monday, March 18th. Finally, ValuEngine cut shares of Zymeworks from a buy rating to a hold rating in a research note on Saturday, May 18th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $9.96.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Tuesday, May 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.26). The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The firm’s revenue for the quarter was down 6.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.01) earnings per share. Sell-side analysts anticipate that Diplomat Pharmacy will post -0.53 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Thrivent Financial for Lutherans raised its position in Diplomat Pharmacy by 2.2% during the 4th quarter. Thrivent Financial for Lutherans now owns 39,424 shares of the company’s stock worth $531,000 after buying an additional 867 shares during the last quarter. Texas Permanent School Fund increased its holdings in shares of Diplomat Pharmacy by 4.1% during the 4th quarter. Texas Permanent School Fund now owns 37,039 shares of the company’s stock valued at $499,000 after purchasing an additional 1,458 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Diplomat Pharmacy by 0.8% during the 4th quarter. New York State Common Retirement Fund now owns 216,819 shares of the company’s stock valued at $2,918,000 after purchasing an additional 1,706 shares in the last quarter. BDO Wealth Advisors LLC purchased a new position in shares of Diplomat Pharmacy during the 4th quarter valued at approximately $27,000. Finally, Great West Life Assurance Co. Can increased its holdings in shares of Diplomat Pharmacy by 8.7% during the 4th quarter. Great West Life Assurance Co. Can now owns 71,458 shares of the company’s stock valued at $886,000 after purchasing an additional 5,702 shares in the last quarter. 79.45% of the stock is owned by institutional investors.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Story: The limitations of an equal weight rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.